Bruker and Humana are facing soft demand from academic institutions and a slowdown in the biopharma market.
2 reports, 1 independent
Updated Aug 4
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bruker and Humana are facing soft demand from academic institutions and a slowdown in the biopharma market.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.Also in this story
- Agilent is discussing revenue growth due to stable demand and biopharma recovery, while also noting how tariff concerns are impacting order trends in China.
- Penumbra is facing growth impacts due to uncertainties regarding FDA review timelines and revenue decline in China.
- Harvard Bioscience is facing revenue decline due to macro uncertainty over tariffs and ongoing issues regarding NIH funding.
The entities involved
Coverage
Newest first; wire copies grouped- StockStoryWhy Bruker (BRKR) Shares Are Getting Obliterated Today Shares of scientific instrument company Bruker (NASDAQ:BRKR). fell 13.8% in the afternoon session after the company released disappointing preli